Combined modality therapy

Is it necessary for everyone?

Matthew R. Porembka, Martin R. Weiser

Research output: Contribution to journalArticle

Abstract

Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and survival in patients with advanced rectal tumors (T3/4) or those with nodal involvement (N1/2). With the broad application of trimodality therapy, concern for over-treatment in select groups of patients exists. Current investigations are now focused on identifying subsets of favorable-risk patients who may benefit from tailored therapy and reducing exposure to unnecessary treatment-related risk.

Original languageEnglish (US)
Pages (from-to)151-154
Number of pages4
JournalSeminars in Colon and Rectal Surgery
Volume24
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Combined Modality Therapy
Rectal Neoplasms
Therapeutics
Implosive Therapy
Recurrence
Survival Rate
Radiation
Drug Therapy
Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Surgery

Cite this

Combined modality therapy : Is it necessary for everyone? / Porembka, Matthew R.; Weiser, Martin R.

In: Seminars in Colon and Rectal Surgery, Vol. 24, No. 3, 09.2013, p. 151-154.

Research output: Contribution to journalArticle

@article{7299a610da554e3da0a0ef9d46766824,
title = "Combined modality therapy: Is it necessary for everyone?",
abstract = "Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and survival in patients with advanced rectal tumors (T3/4) or those with nodal involvement (N1/2). With the broad application of trimodality therapy, concern for over-treatment in select groups of patients exists. Current investigations are now focused on identifying subsets of favorable-risk patients who may benefit from tailored therapy and reducing exposure to unnecessary treatment-related risk.",
author = "Porembka, {Matthew R.} and Weiser, {Martin R.}",
year = "2013",
month = "9",
doi = "10.1053/j.scrs.2013.03.008",
language = "English (US)",
volume = "24",
pages = "151--154",
journal = "Seminars in Colon and Rectal Surgery",
issn = "1043-1489",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Combined modality therapy

T2 - Is it necessary for everyone?

AU - Porembka, Matthew R.

AU - Weiser, Martin R.

PY - 2013/9

Y1 - 2013/9

N2 - Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and survival in patients with advanced rectal tumors (T3/4) or those with nodal involvement (N1/2). With the broad application of trimodality therapy, concern for over-treatment in select groups of patients exists. Current investigations are now focused on identifying subsets of favorable-risk patients who may benefit from tailored therapy and reducing exposure to unnecessary treatment-related risk.

AB - Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and survival in patients with advanced rectal tumors (T3/4) or those with nodal involvement (N1/2). With the broad application of trimodality therapy, concern for over-treatment in select groups of patients exists. Current investigations are now focused on identifying subsets of favorable-risk patients who may benefit from tailored therapy and reducing exposure to unnecessary treatment-related risk.

UR - http://www.scopus.com/inward/record.url?scp=84883032045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883032045&partnerID=8YFLogxK

U2 - 10.1053/j.scrs.2013.03.008

DO - 10.1053/j.scrs.2013.03.008

M3 - Article

VL - 24

SP - 151

EP - 154

JO - Seminars in Colon and Rectal Surgery

JF - Seminars in Colon and Rectal Surgery

SN - 1043-1489

IS - 3

ER -